• A novel transmembrane CXCR4 variant that expands the WHIM genotype-phenotype paradigm
• A phase 3 randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome
• A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome
• A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome
• Behavioral scales variability in patients with prolonged disorders of consciousness
• Can we identify WHIM in infancy? Opportunities with the public newborn screening process
• Congenital neutropenia: From lab bench to clinic bedside and back
• CRISPR/Cas9-mediated Cxcr4 disease allele inactivation for gene therapy in a mouse model of WHIM syndrome
• CXCR4 Antagonist in HPV5-Associated Perianal Squamous-Cell Carcinoma
• CXCR4 as a rheostat of humoral response
• CXCR4 chemokine antagonist scores a first FDA approval for WHIM syndrome
• CXCR4 WHIM syndrome is a cancer predisposition condition for virus-induced malignancies
• Dale DC, Firkin F, Bolyard AA, et al. Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome. Blood. 2020;136(26):2994-3003
• Disease Progression of WHIM Syndrome in an International Cohort of 66 Pediatric and Adult Patients
• Dysregulated stem cell niches and altered lymphocyte recirculation cause B and T cell lymphopenia in WHIM syndrome
• Early detection of WHIM symdrome. A case report
• Expanding CXCR4 variant landscape in WHIM syndrome: integrating clinical and functional data for variant interpretation
• Gene silencing on a WHIM
• Genotype-phenotype correlations in WHIM syndrome: a systematic characterization of CXCR4^WHIM variants
• Historical Cohort of Severe Congenital Neutropenia in Iran: Clinical Course, Laboratory Evaluation, Treatment, and Survival
• Interplay between androgen and CXCR4 chemokine signaling in myelin repair
• Mavorixafor: a new hope for WHIM syndrome
• Mavorixafor: First Approval
• Periodontal disease in patients with WHIM syndrome
• Phase 3 randomized trial of mavorixafor, CXCR4 antagonist, in WHIM syndrome
• Plerixafor for pathogen-agnostic treatment in murine thigh infection and zebrafish sepsis
• Reactogenicity and immunogenicity of the second COVID-19 vaccination in patients with inborn errors of immunity or mannan-binding lectin deficiency
• Reduced G protein signaling despite impaired internalization and beta-arrestin recruitment in patients carrying a CXCR4Leu317fsX3 mutation causing WHIM syndrome
• Reduced G protein signaling despite impaired internalization and β-arrestin recruitment in patients carrying a CXCR4Leu317fsX3 mutation causing WHIM syndrome
• Severe CD8+ T Lymphopenia in WHIM Syndrome Caused by Selective Sequestration in Primary Immune Organs
• The complex nature of CXCR4 mutations in WHIM syndrome
• The promise of novel treatments for severe chronic neutropenia
• Unexpected Diagnosis of WHIM syndrome in Refractory Autoimmune Cytopenia
• Vedolizumab for children with intestinal graft-versus-host disease: a case report and literature review
• WHIM Syndrome-linked CXCR4 mutations drive osteoporosis
• WHIM Syndrome: First Reported Case in a Patient of African Ancestry